Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2021, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 9, 5, 15 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 3 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Allergy Therapeutics Plc

AlphaVax Inc

Ansun Biopharma Inc

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Brandenburg Antiinfektiva GmbH

Celltrion Inc

Changchun Bcht Biotechnology Co Ltd

Chicago Biosolutions Inc

Cidara Therapeutics Inc

CSL Ltd

Emergent BioSolutions Inc

FluGen Inc

Gamma Vaccines Pty Ltd

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

Institute of Virology Vaccines and Sera Torlak

InvVax Inc

Jiangsu Ab&b Biotechnology Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Medicago Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Novavax Inc

PrEP Biopharm Ltd

Sanofi

Sciogen Inc

Seqirus Ltd

Serum Institute of India Pvt Ltd

Shanghai Institute of Biological Products Co Ltd

Trellis Bioscience Inc

Vacthera BioTech GmbH

Table of Contents

Table of Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections - Overview

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections - Drug Profiles

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects

Influenza A Virus, H3N2 Subtype Infections - Discontinued Products

Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Alla Chem LLC, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Allergy Therapeutics Plc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AlphaVax Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Ansun Biopharma Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AstraZeneca Plc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by BlueWillow Biologics Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Brandenburg Antiinfektiva GmbH, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Chicago Biosolutions Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cidara Therapeutics Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by CSL Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Gamma Vaccines Pty Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by ILiAD Biotechnologies LLC, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by InvVax Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by PrEP Biopharm Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sciogen Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Seqirus Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Serum Institute of India Pvt Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Trellis Bioscience Inc, 2021

Influenza A Virus, H3N2 Subtype Infections – Pipeline by Vacthera BioTech GmbH, 2021

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2021

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2021 (Contd..1)

Influenza A Virus, H3N2 Subtype Infections – Dormant Projects, 2021 (Contd..2)

Influenza A Virus, H3N2 Subtype Infections – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports